Quinacrine Treatment of Nitroimidazole-Refractory Giardiasis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34036328.
- Also identified by DOI 10.1093/infdis/jiab287 and PMC identifier 9113433.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Limited evidence exists on efficacy and tolerability of quinacrine for nitroimidazole-refractory giardiasis. Nitroimidazole-refractory giardiasis cases, defined as microbiologically (microscopy and/or PCR) confirmed treatment failure after 2 courses, during 2008-2020, were retrospectively identified. Of 87 patients, 54 (62%) had visited India. Quinacrine was used in 54 (62%); 51 received monotherapy and 3 combined with metronidazole. Only 3 had positive stool samples with persisting symptoms after quinacrine treatment (94% parasitological efficacy) and all were cured after a second treatment. One (1.9%) had mild adverse effects recorded. Quinacrine is an effective treatment for nitroimidazole-refractory giardiasis with good tolerability.
Medical subject headings
- Antiprotozoal Agents
- Giardiasis
- Nitroimidazoles